Cargando…
Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights
The Androgen Receptor (AR) is emerging as an important factor in the pathogenesis of breast cancer (BC), which is the most common malignancy among females worldwide. The concordance of more than 70% of AR expression in primary and metastatic breast tumors implies that AR may be a new marker and a po...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024330/ https://www.ncbi.nlm.nih.gov/pubmed/31952272 http://dx.doi.org/10.3390/molecules25020358 |
_version_ | 1783498410535419904 |
---|---|
author | Anestis, Aristomenis Zoi, Ilianna Papavassiliou, Athanasios G. Karamouzis, Michalis V. |
author_facet | Anestis, Aristomenis Zoi, Ilianna Papavassiliou, Athanasios G. Karamouzis, Michalis V. |
author_sort | Anestis, Aristomenis |
collection | PubMed |
description | The Androgen Receptor (AR) is emerging as an important factor in the pathogenesis of breast cancer (BC), which is the most common malignancy among females worldwide. The concordance of more than 70% of AR expression in primary and metastatic breast tumors implies that AR may be a new marker and a potential therapeutic target among AR-positive breast cancer patients. Biological insight into AR-positive breast cancer reveals that AR may cross-talk with several vital signaling pathways, including key molecules and receptors. AR exhibits different behavior depending on the breast cancer subtype. Preliminary clinical research using AR-targeted drugs, which have already been FDA-approved for prostate cancer (PC), has given promising results for AR-positive breast cancer patients. However, since the prognostic and predictive value of AR positivity remains uncertain, it is difficult to identify and stratify patients that would benefit from AR-targeted therapies. Herein, through a review of preclinical studies, clinical studies, and clinical trials, we summarize the biology of AR, its prognostic and predictive value, as well as its therapeutic implications by breast cancer molecular subtype. |
format | Online Article Text |
id | pubmed-7024330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70243302020-03-11 Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights Anestis, Aristomenis Zoi, Ilianna Papavassiliou, Athanasios G. Karamouzis, Michalis V. Molecules Review The Androgen Receptor (AR) is emerging as an important factor in the pathogenesis of breast cancer (BC), which is the most common malignancy among females worldwide. The concordance of more than 70% of AR expression in primary and metastatic breast tumors implies that AR may be a new marker and a potential therapeutic target among AR-positive breast cancer patients. Biological insight into AR-positive breast cancer reveals that AR may cross-talk with several vital signaling pathways, including key molecules and receptors. AR exhibits different behavior depending on the breast cancer subtype. Preliminary clinical research using AR-targeted drugs, which have already been FDA-approved for prostate cancer (PC), has given promising results for AR-positive breast cancer patients. However, since the prognostic and predictive value of AR positivity remains uncertain, it is difficult to identify and stratify patients that would benefit from AR-targeted therapies. Herein, through a review of preclinical studies, clinical studies, and clinical trials, we summarize the biology of AR, its prognostic and predictive value, as well as its therapeutic implications by breast cancer molecular subtype. MDPI 2020-01-15 /pmc/articles/PMC7024330/ /pubmed/31952272 http://dx.doi.org/10.3390/molecules25020358 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Anestis, Aristomenis Zoi, Ilianna Papavassiliou, Athanasios G. Karamouzis, Michalis V. Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights |
title | Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights |
title_full | Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights |
title_fullStr | Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights |
title_full_unstemmed | Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights |
title_short | Androgen Receptor in Breast Cancer—Clinical and Preclinical Research Insights |
title_sort | androgen receptor in breast cancer—clinical and preclinical research insights |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024330/ https://www.ncbi.nlm.nih.gov/pubmed/31952272 http://dx.doi.org/10.3390/molecules25020358 |
work_keys_str_mv | AT anestisaristomenis androgenreceptorinbreastcancerclinicalandpreclinicalresearchinsights AT zoiilianna androgenreceptorinbreastcancerclinicalandpreclinicalresearchinsights AT papavassiliouathanasiosg androgenreceptorinbreastcancerclinicalandpreclinicalresearchinsights AT karamouzismichalisv androgenreceptorinbreastcancerclinicalandpreclinicalresearchinsights |